Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity
Based on Obesity Canada guidelines and clinical trials (typically over ~1 year): Saxenda: ~58% total body weight loss Wegovy: ~1015% total body weight loss Tirzepatide: ~1520% (or more) total body weight loss weight loss is gradual and occurs over several months, with the most significant changes seen after reaching the full therapeutic dose results vary depending on adherence, lifestyle factors, and individual response 7
At the recommendation from an Independent Data Monitoring Committee, the FLOW study was stopped early due to meeting pre-specified efficacy criteria after a median follow-up of 3.4 years
doi: 10.1111/dom.12748 94 Nexe-LarsenCCSrensenPHHausnerHAgersnapMBaekdalMBrndenAet al
Heres a breakdown of current prices: Wegovy (pill): $199 Wegovy (injectable): $349 Ozempic: $1,027.51 Mounjaro: $1,112.16 Zepbound: $1,086.37 Saxenda: $1,349.02 What to do if your insurance doesnt cover GLP1s I often tell my patients to see insurance denial as a detour and not a dead end, says Nneoma Oparaji, a telemedicine physician at MDLIVE, a 24/7 on-call physician platform